SCHEMBL3229060

SCHEMBL3229060

Cc1cc(C)c(S(=O)(=O)NC(CNc2ccccc2C)C(C)C)c(C)c1

nearest known ligand 0.56

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 19/20 0.56
PGR P06401 6/20 0.50
NR3C2 P08235 5/20 0.50
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MCOLN3 Q8TDD5 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3219756 0.89 NR3C1 (0.54) NR3C1PGRNR3C2CYP3A4
SCHEMBL3227021 0.86 NR3C1 (0.67) NR3C1PGRNR3C2LMNA
SCHEMBL3220629 0.84 NR3C1 (0.45) NR3C1PGRNR3C2CYP3A4
SCHEMBL3223693 0.81 NR3C1 (0.51) NR3C1PGRNR3C2
SCHEMBL3213636 0.81 NR3C1 (0.76) NR3C1PGRNR3C2CYP3A4
SCHEMBL4441200 0.81 L3MBTL1 (0.49) NR3C1PGRNR3C2LMNASMN1; SMN2
SCHEMBL3222286 0.75 NR3C1 (0.54) NR3C1PGRNR3C2LMNA
SCHEMBL3220663 0.74 NR3C1 (0.68) NR3C1PGRNR3C2LMNASMN1; SMN2
SCHEMBL3223117 0.74 NR3C1 (0.68) NR3C1PGRNR3C2LMNASMN1; SMN2
SCHEMBL4119637 0.74 NR3C1 (1.00) NR3C1PGRCYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100048950-A1 Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-25 US claimed
EP-2136811-A1 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF Boehringer Ingelheim International GmbH (DE) 2009-12-30 EP claimed
WO-2008124745-A1 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-10-16 WO claimed
US-20100048950-A1 Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-25 US disclosed
EP-2136811-A1 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF Boehringer Ingelheim International GmbH (DE) 2009-12-30 EP disclosed
WO-2008124745-A1 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048950-A1 Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof NR3C1, MC2R, NR3C2 NR3C1 1/4885PGR 88/4885NR3C2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.